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Abstract
Male breast cancer accounts for 1% of all breast cancer cases, and men tend to be diagnosed at an older age than
women (mean age is about 67 years). Several risk factors have been identified, such as genetic and hormonal
abnormalities.
The present study reported the case of a 25-year-old man who was diagnosed with an advanced invasive ductal
carcinoma; however, he did not have any important risk factors.
Even though more data is emerging about this disease, more efforts to understand risk factors, treatment options
and survival benefits are needed. In this case, we discussed the risk factors as well as the impaired fertility
associated with breast cancer therapies.
Background
Breast cancer in men is rare, and it accounts for about
1% of all malignant breast neoplasm cases [1,2]. The
estimated incidence is 1 case for each 100,000 men. In
the United States, about 1,910 new cases were diagnosed
in 2009, and 440 of these cases resulted in death [3].
Among the histologic types, invasive ductal carcinoma is
the most prevalent breast cancer in males, with an inci-
dence varying from 65 to 95% [2,4].
Male breast cancer has unimodal age-frequency distri-
bution with a peak incidence at 71 years old. Conver-
sely, female breast cancer has a bimodal age-frequency
distribution with early-onset and late-onset peak inci-
dences at 52 and 72 years old, respectively [5].
This study examined a 25-year-old man without
important risk factors who was diagnosed with invasive
ductal carcinoma. Although it is rare, there have been
instances of breast cancer in younger males [6]. We
evaluated the main aspects of the epidemiology of
breast neoplasm in men and the best approach for
treatment.
Case presentation
A 25-year-old Brazilian male was referred to our institu-
tion in August 2007 complaining of a breast tumor of
progressive growth for the previous eight months. Pre-
vious medical and family history did not appear to con-
tribute to the present illness. He denied using drugs or
anabolic steroids and did not drink alcohol. The only
medication he was taking was phenobarbital, which he
had been taking for four years since he presented with
two seizure episodes. The patient was a smoker who
consumed 10 cigarettes per day. He also reported a nor-
mal sexual life, but he did not have children.
Physical examination revealed a 3.5 cm tumor located
on the right breast. There was a retraction of the nipple;
the nodule, which could be moved, had a hardened con-
sistency and did not adhere to deep planes. The armpits
did not present lymphadenopathy.
Mammographic findings consisted of a noncalcified
high density mass (Figure 1) and breast ultrasonography
revealed a hypoechogenic nodule of irregular shape with
partially defined limits measuring 17 × 13 × 11 mm in
the right breast. The magnetic nuclear resonance imaging
showed a retroareolar nodule in the right breast, which
corresponded to an expansive process. There were also
signs of infiltration of the pectoralis muscle and a small
area of retroareolar highlight in the left breast. Final
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Breast Imaging Reporting and Data System (BI-RADS)
category was 5: highly suggestive of malignancy.
Fine-needle aspiration and a core biopsy of the lesion
were performed, and the diagnosis was invasive ductal car-
cinoma (Figure 2). After a recommended sperm cryopre-
servation, the patient started neoadjuvant chemotherapy
(4 × FEC 100 + 1 cisplatin 75 with adriamycin 60). In
February 2008, the patient was submitted to a modified
radical mastectomy (right breast) and retroareolar lum-
pectomy (left breast) (Figure 3).
The anatomopathological analysis confirmed the diag-
nosis of invasive ductal carcinoma with a 3.0-cm lesion
in the biggest axle, which was histologic grade 2 and
nuclear grade 2. Final breast surgical margins were free,
but pectoralis muscle fascia and the nipple were infil-
trated. The axillary lymph nodes dissection did not
show any signs of cancer (0/8). In addition, immunohis-
tochemical staining of the tumor was positive for estro-
gen and progesterone receptors, and HER-2 negative
(Score 1). Although there were no signs of malignancy
or atypical hyperplasia in the left breast tissue, there was
fibrosclerosis and benign fibroadipose tissue.
The patient received adjuvant therapy along with
radiation therapy (5,000 cGy), and tamoxifen (20 mg/
day). Post-therapy follow-up were performed by mem-
bers of the treatment team and included regular physical
examinations and history. Liver function and alkaline
phosphatase tests were not indicated during the time
the patient was taking endocrine therapy. Although
reports have appeared about the dangers of liver damage
and hepatoma resulting from tamoxifen administration,
results from NSABP studies attest such concerns have
not been substantiated [7].
One year after the radiation therapy ended, the patient
presented with cervical and dorsal nodules, jaundice and
weight loss (about 20 kg). Evaluation of suspicious
recurrent breast cancer included physical exam, the per-
formance of a CBC, platelet count, liver function tests,
chest imaging, bone scan and an abdomen ultrasound.
Blood tests results were negative for hepatitis A, B and
C, serum glutamic oxaloacetic transaminase 241 IU/L
(normal range: 10-34), serum alanine aminotransferase
187 IU/L (7-50), lactate dehydrogenase 358 U/L
(50-150), total bilirubin 8.69 mg/dl (0.3-1.9), direct bilir-
ubin 8.40 mg/dl (0-0.3) and alkaline phosphatase
959 IU/L (20-140).
In October 2009, the abdominal ultrasonography
showed the presence of several hepatic nodules. The
general state of the patient was deteriorating. He had a
variety of symptoms, including a lower level of con-
sciousness, dysphagia, inappetence, fever, cyanosis, and
dyspnea. The patient quickly developed multiple organ
failure and died in November 2009.
Because of weakness and quick deterioration of health
state of the patient, it was not possible to perform a
biopsy documentation of recurrence and determination
of hormone receptor status and HER-2 status.
Discussion
Invasive ductal carcinoma in men presents peculiar
features. About 42% of breast cancer cases in men are
diagnosed in stage III or IV [1]. This is probably because
men do not seek medical attention for breast masses as
quickly as women. In addition, the tumor is usually clo-
ser to the skin in males, which increases the likelihood
Figure 1 Mammographic findings. Noncalcified high density
mass of right breast.
Figure 2 Histological biopsy: invasive ductal carcinoma
(hematoxylin-eosin staining).
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of infiltration into the dermis, which was reported in the
present case.
Treatment strategies for male breast cancer are not
based on data from randomized clinical studies in men
and most treatment recommendations are extrapolated
from data in women [8].
Men with breast carcinoma have a poor prognosis,
especially in the younger age group, because most breast
enlargements in young men are dismissed as gyneco-
mastia [9,10]. This potential misdiagnosis can result in
an unnecessary delay in treatment. The median age of
breast cancer diagnosis in men is approximately 65
years old [11]. Reports of breast cancer in young male
patients are rare. Nielsen and Jakobsen described a
breast cancer case in a 32-year-old man [12]. More
recently, an invasive cancer case was reported in a
30-year-old patient [9]. In 2008, Chang et al. described
the case of a 16-year-old male with unilateral ductal
carcinoma in situ and gynecomastia [13].
There is a close relation between the BRCA2 gene
mutation and male breast cancer. It has also been
observed, however, that some cases involve BRCA1
participation [14-16]. Other conditions that have been
associated with the occurrence of breast neoplasms in
men are cirrhosis [17], testicular trauma, obesity, radia-
tion therapy exposure, and the use of exogenous estro-
gen [18]. In addition to the very young age of the
patient in the present report, this patient did not have a
family, hormonal, or genetic history that could justify
the high risk for breast cancer. Although gynecomastia
has been suggested to be present in 6-38% of breast
cancer cases in men [19], it was not evident in our
patient.
It is fundamental to consider the history of breast
tumors in first-degree relatives because that can be an
indicator for increased breast cancer risk. Indeed,
genetic diseases such as Klinefelter’s syndrome and
Cowden’s disease have been shown to be related to
breast cancer in men [1].
There is no evidence that suggests that all men need
breast magnetic nuclear resonance imaging (MRI). But
suspicious MRI lesions in the contralateral breast should
be examined. Furthermore, male breast cancer survivors
have an increased risk of developing a second primary
Figure 3 Surgery. Modified radical mastectomy (right breast) and retroareolar lumpectomy (left breast).
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cancer. The risk of a contralateral breast cancer appears
to be higher for men than it is for women [20]. Some
studies indicate that men with breast cancer have a 30-
fold increased risk of contralateral breast cancer, much
greater than the two- to fourfold risk among women
with breast cancer [21]. The risk of subsequent contral-
ateral breast cancer was highest for men aged less than
50 years at the time of the first cancer diagnosis, which
is consistent with studies of women with breast cancer
[22,23].
Estrogen receptors and progesterone receptors have
been suggested to play a role in breast cancers in men,
and they are present in about 90% and 81% of breast
cancers in males, respectively [4]. Furthermore, overex-
pression of the proto-oncogene HER-2 has been shown
to present the worst prognosis for a patient [24]. Other
markers that have been recently studied are p27, MIB-1
and Bcl-2 genes.
Similar to breast cancer cases in women, earlier detec-
tion of male breast cancer is correlated with the success
of the treatment. Although males have considerably less
mammary parenchyma than women, the investigation
must be a combination of a clinical exam, mammogra-
phy, cytology, and percutaneous biopsies [25,26]. The
core needle biopsy is important because it enables a
definitive diagnosis of invasive breast cancer and the
evaluation of estrogen receptors, progesterone receptors,
and Her-2 status [3].
Tamoxifen should still be considered as the optimal
adjuvant therapy option for male patients with endo-
crine responsive disease. The effect regarding rate and
overall survival by adjuvant chemotherapy is also far less
well studied [8]. Some studies have demonstrated an
improved disease-free and overall survival compared
with historical controls using adjuvant anthracycline-
based therapies [4,5,27].
Because of the high probability of an indefinite period
of infertility following chemotherapy, sperm cryopreser-
vation should be recommended for all young patients
with cancer prior to the start of chemotherapy.
Although treatment and survival represent the primary
goals of the clinical approach towards breast cancer
patients, the quality of life after treatment, including the
possibility of becoming fathers, requires consideration.
In addition, sperm cryopreservation is another hope that
encourages young patients with cancer during and after
treatment [28].
Breast cancer therapeutics in men must be based on cer-
tain parameters, such as tumor size, the presence of estro-
gen and progesterone receptors, HER-2 expression, and
the association with other diseases. Men diagnosed with
breast cancer present risk factors, such as chronic hepato-
pathies, that are directly associated with the neoplasm. In
addition, men diagnosed with breast cancer are generally
older and present other comorbidities. Due to the smaller
size of male mammary parenchyma, the elected surgical
treatment is modified radical mastectomy.
Conclusions
Invasive ductal carcinoma in young men is extremely
rare; the peak incidence is around the seventh decade of
life. Risk factors for male breast cancer include genetic
factors and hormonal abnormalities. Despite an absence
of a familial history of breast cancer, hormonal abnorm-
alities, or a genetic disease, the male patient in the pre-
sent study developed breast cancer at a very young age.
The causative factors in this patient were unable to be
definitively identified. The pathophysiology of breast
cancer in males is not adequately understood. As more
cases of breast cancer in young male patients are inves-
tigated, we may be able to gain a better understanding
of the mechanism.
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